I-Mab Biopharma
IMAB
#9150
Rank
S$0.10 B
Marketcap
$1.25
Share price
-3.17%
Change (1 day)
-39.09%
Change (1 year)

Revenue for I-Mab Biopharma (IMAB)

Revenue in 2024 (TTM): S$4.75 Million

According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is S$4.86 Million. In 2022 the company made a revenue of -S$43.54 Million a decrease over the revenue in the year 2021 that were of S$18.72 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for I-Mab Biopharma from 2017 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) S$4.75 M
2022-S$43.54 Million-332.55%
2021S$18.72 M-94.16%
2020 S$0.32 B5407.66%
2019 S$5.82 M-45.08%
2018 S$10.59 M340.25%
2017S$2.4 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
S$0.3 M-93.70%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.96 B 19,728.62%๐Ÿ‡บ๐Ÿ‡ธ USA